HOOKIPA PharmaHOOK 50 Receivables Turnover is 9.39 as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 50/100. Among 839 Biotechnology companies, HOOKIPA Pharma ranks better than 94.16% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. HOOKIPA Pharma's Revenue for the
three
months ended in Jun. 2025 was $6.80 Mil. HOOKIPA Pharma's average Accounts Receivable for the
three
months ended in Jun. 2025 was $0.72 Mil.
Hence, HOOKIPA Pharma's Receivables Turnover for the
three
months ended in Jun. 2025 was 9.39.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
HOOKIPA Pharma Receivables Turnover Related Terms
HOOKIPA Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for HOOKIPA Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOK vs COCP, LNAI, CYCN: Receivables Turnover Comparison
For the Biotechnology subindustry, HOOKIPA Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma (HOOK) has a Receivables Turnover of 9.39 as of Jun. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on HOOKIPA Pharma and its competitors. According to the industry distribution chart, HOOKIPA Pharma ranks #49 out of 839 companies in the Biotechnology industry, placing it in the top 5.8%.
Is HOOKIPA Pharma's Receivables Turnover too high?
HOOKIPA Pharma's current Receivables Turnover is 9.39. The Biotechnology industry median Receivables Turnover is 5.29. HOOKIPA Pharma's value of 9.39 is 77.5% above this industry median. Based on the distribution chart, HOOKIPA Pharma ranks #49 out of 839 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HOOKIPA Pharma has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Receivables Turnover compare to COCP and LNAI?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #49 out of 839 companies for Receivables Turnover. This places HOOKIPA Pharma in the top 6% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. HOOKIPA Pharma's value of 9.39 is 77.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOOKIPA Pharma's current Receivables Turnover of 9.39 is 77.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on HOOKIPA Pharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOOKIPA Pharma's current Receivables Turnover is 9.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
HOOKIPA Pharma (HOOK) has a current Receivables Turnover of 9.39. The current Receivables Turnover is 9.39 and 77.5% above the Biotechnology industry median of 5.29. HOOKIPA Pharma's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Receivables Turnover is 9.39 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score
Get the complete analysis for HOOK
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 
